Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03276195 |
| Other study ID # |
vnarayanan15-016 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 1, 2016 |
| Est. completion date |
November 27, 2023 |
Study information
| Verified date |
November 2023 |
| Source |
Translational Genomics Research Institute |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study is aimed to carry out a systematic study to examine the effects of genetic
variants (genetic modifiers) other than TSC genes on phenotypic variability in familial TSC
patients (affected parent, child and unaffected siblings) and sporadic TSC.
Description:
Tuberous sclerosis complex (TSC) is an autosomal dominant neurogenetic disorder, caused by
heterozygous mutations in at least two different genes, TSC1, and TSC2. It is estimated to
affect 1 in 6000, and demonstrates both phenotypic and genetic heterogeneity. It is
characterized by a variety of symptoms including skin lesions, renal angiomyolipomas, cardiac
rhabdomyomas, seizures, and cognitive delay (mental retardation, autism, and behavior
problems). The severity of the disease varies widely among patients with TSC in general, and
variability in phenotype is detectable within single families, where all affected individuals
have the same TSC1 or TSC2 mutation. Neurocognitive phenotypes in TSC vary from profound
mental retardation, intractable epilepsy, and autism, to normal cognition and only a mild
behavioral phenotype. However, the basis of this phenotypic variability is not understood.
There is a growing body of literature implicating genetic variation in "modifier genes" as an
agent for phenotypic heterogeneity in Mendelian disorders, such as TSC. The role of genetic
modifiers on disease severity has not yet studied in familial TSC and sporadic TSC. This
study is aimed to carry out a systematic study to examine the effects of genetic variants
other than TSC genes on phenotypic variability in familial TSC patients (affected parent,
child and unaffected siblings) and sporadic TSC. The main objectives of the study are:
1. To identify new gene mutations (genetic modifiers) in TSC familial pairs and sporadic
cases that account for the phenotypic variability.
2. Determination of quantitative differences in gene expression and allelic expression
imbalance between mild and severe disease phenotype.
3. Establish a specimen repository of familial and sporadic TSC cohort to validate the
genetic modifiers.
To identify genetic variants that differentiate disease severity using next generation
sequencing (NGS) in DNA, and gene expression profile in RNA from blood to identify
disease-causing heterozygous TSC(1 or 2) mutation in parent-child (P-C) pairs and sporadic
cases with a mild and severe form of the disease. Use of next-generation sequencing (NGS)
along with improved data analysis in this proposal will overcome many of the barriers in
identifying genetic modifiers. The investigators will also study cultured fibroblasts cells
and buccal swabs from P-C pairs to validate the findings. Use of next-generation sequencing
(NGS) along with improved data analysis in this proposal will overcome many of the barriers
in identifying genetic modifiers. This research has the potential to address a critical
scientific gap in understanding the phenotypic variability The investigators may be able to
develop a "molecular profile" that correlates with and predicts disease severity. The
findings may provide a tool for early prediction of disease severity, allowing for the use of
disease modifying treatments that may prevent the development of a severe neurocognitive
phenotype.
As this is not a treatment protocol, there is no primary endpoint.
Read more »
